Metallic blood vessel bracket coating for osamine glycan load CD133 antibody and method for preparing the same

Abstract

The invention relates to a metallic blood vessel supporting rack coating layer of an amine glycan load antibody and the preparation method thereof. The invention selects chitosan and hyaluronic acid and other natural amine glycan which can perform biological degradation as carrier material, the static self assembly technology is adopted, a CD133 antibody is firstly fixed in the metallic blood vessel supporting rack millimicron coating layer, a carrier has good biological compatibility, moisture, flexibility, washing resistance and biological stability. After a CD133 antibody coating supporting rack is embedded in human bodies, blood vessel endothelial cell in circumferential blood liquid can be quickly caught in a specificity way, the good biological compatibility of the amine glycan carrier provides a proper occasion for blood vessel endothelial cell differentiation, the surface of the supporting rack is coved by the differentiated single layer blood vessel endothelial cell within two days, the formation of a partial false inner membrane is effectively avoided, thereby accelerating blood vessel endothe and quickly repairing the wound of a blood vessel inner membrane caused by the expansion of sacculus during the implantation process of the supporting rack, and the invention is new measures to naturally and safely prevent the formation of thrombus and narrow down again.

Description

technical field [0001] The invention relates to a formulation and a preparation method of a metal vascular stent biological antibody coating in the field of medical instruments. Background technique [0002] Coronary artery and peripheral vascular embolism have become the number one killer that endangers human health, and intravascular stenting has become one of the most effective means to rapidly alleviate such diseases. However, the bare metal stent itself is mostly made of metal materials. Implantation into the blood vessel can cause inflammatory reactions, long-term stretching in the blood vessel leads to intimal hyperplasia, and further stimulates the secretion of growth factors and cytokines, eventually leading to smooth muscle cell hyperplasia and migration, causing in-stent restenosis. Drug-coated metal vascular stents such as the second-generation anti-rejection drug rapamycin and the anticancer drug paclitaxel have significantly reduced the incidence of restenosis...

AI Technical Summary

Problems solved by technology

However, the CD34 monoclonal antibody is immunoglobulin IgG, which is a water-soluble proteoglycan, while the coating carrier material is a fat-soluble material such as polytetrafluoroethylene, and there is almost no biocompatibility between the two

When polytetrafluoroethylene tetrahydrofuran solution is mixed with CD34 antibody aqueous solution, emulsified and coated on the surface of the metal stent, after drying, the protein secondary structure of the natural state of CD34 antibody is gradually changed in an anhydrous system to make it inactivated, so this This kind of CD34 antibody scaffold can not meet the shelf life requirements of the product, and it is difficult to commercialize it on a large scale

Kutryk et al. also chemically cross-linked the CD34 antibody to a synthetic polymer, and then coated it on a metal vascular stent. The main problem of this chemical cross-linking is not only that some determinants of the antibody are chemically bonded to cause inactivation, but also There is a problem with the gradual inactivation of antibodies in anhydrous coatings

In addition, the CD34 antibody lacks specificity to EPCs. While adsorbing EPCs, it can also adsorb other endothelial cells with CD34 antigens. The polytetrafluoroethylene carrier also cannot provide a suitable place for the differentiation of vascular endothelial cells, and the result may be localized. Formation of "pseudointima"

Images